United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - adults risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia .pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy - adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)]. due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone dru

United States - English - NLM (National Library of Medicine)

doh central pharmacy - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - adults risperidone is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)] . adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy – adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)] . due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug produ

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in four short-term trials in adults, two short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)]. risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in two short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)]. risperidone tablets adjunctive therapy with lithium or valproate are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)]. risperidone tablets are indicated for the treatment of irritability associated with autistic disorder including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums and quickly ch

United Kingdom - English - myHealthbox

rosemont pharmaceuticals ltd - risperidone - oral solution - 1mg/ml - other antipsychotics - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer's dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.; for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to dsm-iv criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment.

Malta - English - Medicines Authority

mylan pharmaceuticals limited damastown industrial park mulhuddart dublin15 dublin, ireland - risperidone - orodispersible tablet - risperidone 1 mg - psycholeptics

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - risperidone 1 mg/ml - oral solution - 1 mg/ml - active: risperidone 1 mg/ml excipient: disodium edetate hydroxypropyl-beta-cyclodextrin malic acid potassium hydroxide purified water saccharin sodium sodium methyl hydroxybenzoate - risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperidone also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperidone also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.5 mg - risperidone (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see ]. clinical studies ( ) 14.1 monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see ]. clinical studies ( ) 14.2 adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see ]. clinical studies ( )

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - adults risperidone (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone drug products. monotherapy adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)]. due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone

United States - English - NLM (National Library of Medicine)

torrent pharmaceuticals limited - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)]. monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2) ]. adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3) ]. risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly cha

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)]. risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)]. risperidone tablets adjunctive therapy with lithium or valproate are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)]. risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changin